Gibson James R II sold $2.1M of PACB
Gibson James R II (See Remarks) sold 661,815 shares of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) at $3.11 ($2.06M total) on 2026-10-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is planned via a Rule 10b5-1 arrangement, which generally lowers the informational content relative to non-10b5-1 discretionary selling.
Market read
Traders may monitor PACB for any follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing by itself.
What to watch
Because the transaction is explicitly under a pre-arranged 10b5-1 plan, traders may discount it; any real impact would more likely come from concurrent company-specific catalysts not mentioned here.
Background
The article is an SEC Form 4 insider transaction disclosure for Pacific Biosciences of California, Inc. (PACB).
Ticker impact
PACB Form 4 shows officer Gibson James R II sold 661,815 shares for about $2.06M under a pre-arranged 10b5-1 plan.
Likely limited downside pressure, with the market treating the sale as planned rather than a fresh negative signal.
The filing is a primary SEC Form 4 disclosure, but the presence of a pre-arranged 10b5-1 plan usually reduces interpretive weight versus discretionary selling.
Market effects
Minimal spillover to biotech peers; this is a single-company insider transaction.
None.
None.
Counterpoint
The sale could be interpreted as a signal of liquidity needs or diversification rather than any negative view, so price impact may be negligible.
Key entities
- issuerPACB
Pacific Biosciences of California, Inc., the company whose insider transaction is disclosed.
- insiderGibson James R II
Officer of PACB who sold 661,815 shares on 2026-10-06.
